EYLEA HD is anticipated to gain traction with the launch of a prefilled syringe in mid-2025 and label expansions for macular edema and extended dosing intervals. Management believes these developments ...

The two products, both manufactured by Amgen, are aflibercept biosimilars Pavblu and Skojoy. Both biosimilars are indicated ...

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

After repeatedly wowing investors, Roche’s star eye med Vabysmo collected more than $4 billion in sales during its third year ...

The pre-filled syringe, so I would just like to say right now, we're really not seeing any impact in any part of the world from high-dose EYLEA. And the pre-filled syringe that we have in the ...

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...

EYLEA HD achieved $6 billion in 2024 sales, with FDA decisions on extended dosing and pre-filled syringes due in 2025. Dupixent sales topped $15 billion in 2024, with strong COPD launch and Phase ...

The company’s Eylea product line, particularly the Eylea HD, has promising developments with a pre-filled syringe application on track for a mid-2025 US launch. This positions it to compete effe ...

Primarily, the lower-than-expected sales figures for Eylea’s high dose in the fourth ... benefits and availability as a pre-filled syringe. Moreover, Regeneron has not responded effectively ...

Regeneron Pharmaceuticals, Inc. REGN provided business and pipeline updates at the 43rd Annual J.P. Morgan Healthcare Conference. Shares of the company moved up in pre-market trading on Jan. 14.

Sales of Eylea, which the company co-developed with Bayer (DE:BAYA), rose 2% to $1.495 billion. Sales of the higher-dose, longer-lasting formulation Eylea HD rose 148% to $305 million in the U.S., ...